GRAIL, Inc. (GRAL)
59.99
+1.40
(+2.39%)
USD |
NASDAQ |
Jun 11, 11:00
GRAIL 1 Year Total Returns (Daily) : 39.00% for June 10, 2026
1 Year Total Returns (Daily) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical 1 Year Total Returns (Daily) Data
| Date | Value |
|---|---|
| June 10, 2026 | 39.00% |
| June 09, 2026 | 52.14% |
| June 08, 2026 | 60.38% |
| June 05, 2026 | 51.89% |
| June 04, 2026 | 66.33% |
| June 03, 2026 | 58.57% |
| June 02, 2026 | 59.73% |
| June 01, 2026 | 67.66% |
| May 29, 2026 | 74.40% |
| May 28, 2026 | 79.90% |
| May 27, 2026 | 68.68% |
| May 26, 2026 | 71.63% |
| May 22, 2026 | 73.30% |
| May 21, 2026 | 81.15% |
| May 20, 2026 | 67.93% |
| May 19, 2026 | 59.53% |
| May 18, 2026 | 52.12% |
| May 15, 2026 | 52.99% |
| May 14, 2026 | 87.90% |
| May 13, 2026 | 40.99% |
| May 12, 2026 | 72.21% |
| May 11, 2026 | 74.03% |
| May 08, 2026 | 70.75% |
| May 07, 2026 | 81.27% |
| May 06, 2026 | 95.12% |
| Date | Value |
|---|---|
| May 05, 2026 | 58.79% |
| May 04, 2026 | 55.58% |
| May 01, 2026 | 66.39% |
| April 30, 2026 | 57.94% |
| April 29, 2026 | 35.01% |
| April 28, 2026 | 41.46% |
| April 27, 2026 | 47.90% |
| April 24, 2026 | 44.39% |
| April 23, 2026 | 50.03% |
| April 22, 2026 | 77.16% |
| April 21, 2026 | 93.22% |
| April 20, 2026 | 89.63% |
| April 17, 2026 | 91.52% |
| April 16, 2026 | 86.68% |
| April 15, 2026 | 91.98% |
| April 14, 2026 | 103.2% |
| April 13, 2026 | 106.5% |
| April 10, 2026 | 100.6% |
| April 09, 2026 | 91.00% |
| April 08, 2026 | 137.4% |
| April 07, 2026 | 105.0% |
| April 06, 2026 | 132.5% |
| April 02, 2026 | 110.4% |
| April 01, 2026 | 113.5% |
| March 31, 2026 | 102.3% |
Total Return Definition
The Total return is the change in price over a specific period of time that includes dividends and distributions paid.
1 Year Total Returns (Daily) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
1 Year Total Returns (Daily) Benchmarks
| Apogee Therapeutics, Inc. | 96.86% |
| Evommune, Inc. | -- |
| Arrowhead Pharmaceuticals, Inc. | 316.8% |
| Oncolytics Biotech, Inc. | 87.38% |
| Sangamo Therapeutics, Inc. | -71.08% |